Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other research firms have also recently issued reports on ARCT. Guggenheim cut shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. Citigroup cut their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Thursday, November 13th. Wells Fargo & Company lowered their price target on Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, October 23rd. Leerink Partners dropped their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Arcturus Therapeutics Trading Down 0.8%

Shares of Arcturus Therapeutics stock opened at $7.46 on Friday. The stock has a market capitalization of $211.94 million, a price-to-earnings ratio of -3.03 and a beta of 2.10. Arcturus Therapeutics has a twelve month low of $5.85 and a twelve month high of $24.17. The business’s 50 day simple moving average is $11.10 and its 200-day simple moving average is $13.86.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.60. The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. Sell-side analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently modified their holdings of ARCT. Goldman Sachs Group Inc. boosted its position in Arcturus Therapeutics by 9.1% in the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 42,636 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Arcturus Therapeutics during the first quarter worth approximately $299,000. Invesco Ltd. raised its stake in shares of Arcturus Therapeutics by 83.1% in the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 15,836 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Arcturus Therapeutics in the 2nd quarter worth approximately $240,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Arcturus Therapeutics by 20.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company’s stock worth $1,526,000 after acquiring an additional 24,583 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.